European Commission authorises second safe and effective vaccine against COVID-19

(Credit: Unsplash)

This article is brought to you in association with the European Commission.


Today, the European Commission has granted a conditional marketing authorisation (CMA) for the COVID‑19 vaccine developed by Moderna, the second COVID-19 vaccine authorised in the EU. This authorisation follows a positive scientific recommendation based on a thorough assessment of the safety, effectiveness and quality of the vaccine by the European Medicines Agency (EMA) and is endorsed by the Member States.

The President of the European Commission, Ursula von der Leyen, said: “We are providing more COVID-19 vaccines for Europeans. With the Moderna vaccine, the second one now authorised in the EU, we will have a further 160 million doses. And more vaccines will come. Europe has secured up to two billion doses of potential COVID-19 vaccines. We’ll have more than enough safe and effective vaccines for protecting all Europeans.”

Stella Kyriakides, Commissioner for Health and Food Safety, said: “We are all in this together and united. This is why we have negotiated the broadest vaccine portfolio in the world for all our Member States. Today we are authorising a second safe and effective vaccine from Moderna, which together with BioNTech-Pfizer, will ensure that 460 million doses will be rolled out with increasing speed in the EU, and more will come. Member States have to ensure that the pace of vaccinations follows suit. Our efforts will not stop until vaccines are available for everyone in the EU.”

Moderna submitted on 30 November 2020 an application for marketing authorisation to EMA, which had already started a rolling review of the data in November. Thanks to this rolling review, EMA has been assessing the quality, safety and efficacy of the vaccine as data has become available. EMA’s human medicines committee (CHMP) has thoroughly assessed the data and recommended by consensus that a formal conditional marketing authorisation is granted. A conditional marketing authorisation is one of EU’s regulatory mechanisms for facilitating early access to medicines that fulfil an unmet medical need, including in emergency situations such as the current pandemic.

On the basis of EMA’s positive opinion, the Commission has verified all the elements supporting the marketing authorisation and consulted Member States before granting the conditional market authorisation.

The Moderna vaccine is based on messenger RNA (mRNA). mRNA plays a fundamental role in biology, transferring instructions from DNA to the cells’ protein making machinery. In an mRNA vaccine, these instructions produce harmless fragments of the virus, which the human body uses to build an immune response to prevent or fight disease. When a person is given the vaccine, their cells will read the genetic instructions and produce a spike protein, a protein on the outer surface of the virus which it uses to enter the body’s cells and cause disease. The person’s immune system will then treat this protein as foreign and produce natural defences — antibodies and T cells — against it.

Next steps

Moderna, with whom the Commission signed a contract on 25 November, will deliver the total amount of 160 million doses between the first and the third quarters of 2021. It will add to the 300 million doses of the vaccine distributed by BioNTech/Pfizer, the first vaccine to have been authorised in the EU on 21 December 2020.

Background

A conditional marketing authorisation (CMA) is an authorisation of medicines on the basis of less complete data required for a normal marketing authorisation. Such a CMA may be considered if the benefit of a medicine’s immediate availability to patients clearly outweighs the risk linked to the fact that not all the data are yet available. However, once a CMA has been granted, companies must provide within certain deadlines further data including from ongoing or new studies to confirm that the benefits continue to outweigh the risks.

Moderna submitted on 30 November 2020 an application for a CMA for their vaccine to EMA. EMA has already been assessing data on the vaccine’s safety, effectiveness and quality and results from laboratory studies and clinical trials in the context of a rolling review. This rolling review and the assessment of the CMA application allowed EMA to quickly conclude on the safety, effectiveness and quality of the vaccine. EMA recommended granting the conditional marketing authorisation as the benefits of the vaccine outweigh its risks.

The European Commission has verified whether all necessary elements – scientific justifications, product information, educational material to healthcare professionals, labelling, obligations to marketing authorisation holders, conditions for use, etc. – were clear and sound. The Commission also consulted the Member States, as they are responsible for the vaccines marketing and the use of the product in their countries. Following the Member States’ endorsement and on the basis of its own analysis, the Commission decided to grant the conditional market authorisation.

the sting Milestones

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

6 ways countries can prepare for the next infectious disease pandemic

Moves to create a Kosovo army have ‘deteriorated relations’ with Serbia: UN peacekeeping chief

Smart city experts should be looking to emerging markets. Here’s why

3 unexpected consequences of the US-China trade war

China and China-EU Relations in the New Era

Beyond ‘business as usual’. Addressing the climate change crisis

Eurozone at risk of home-made deflation and recession

We need to give voice to ‘We the Peoples’, says UN chief

With Libyans now ‘fighting the wars of others’ inside their own country, UN envoy urges Security Council action to end violence

German stock market is not affected by the Greek debt revolution while Athens is running out of time

Coronavirus: EU guidance for a safe return to the workplace

5 things COVID-19 has taught us about inequality

Pharmaceuticals: Commission refines intellectual property rules

All States have ‘primary responsibility’ to protect against hate attacks

How the ‘California effect’ could shape a global approach to ethical AI

South Korea: A cherished partner for the EU

Where is heading Putin’s Russia?

New Mozambique storm rips off roofs, brings lashing rain as aid response kicks in

UN refugee agency presses States to aid 49 refugees stranded on Mediterranean

Young translators at EU schools – Commission opens registration for 2020 translation contest

Negotiated two-State solution still ‘the only option’ for Palestine: Guterres

UN political chief calls for dialogue to ease tensions in Venezuela; Security Council divided over path to end crisis

State aid: Commission approves €1.2 billion French “Fonds de solidarité” scheme for small enterprises in temporary financial difficulties due to coronavirus outbreak

These are the top 10 global causes of death – but two diseases are in decline

Brazilian health: right or privilege?

Why the minutes and the months matter most to young people during the COVID-19 crisis

Stop cooperation with and funding to the Libyan coastguard, MEPs ask

Statement by the European Commission following the extraordinary meeting of the EU-UK Joint Committee

Why Eurozone urgently needs the ECB to print and distribute at least €500 billion

The remote doctor in the 21st century

Over 820 million people suffering from hunger; new UN report reveals stubborn realities of ‘immense’ global challenge

“France will be there, it will always be there!”, French President Hollande says in a rather disorganised speech; the Sting reports live from World Economic Forum 2015 in Davos

What just happened? 5 themes from the COP24 climate talks in Poland

More bank bailouts at taxpayers’ expenses

EP wants data protection guaranteed before allowing fingerprint exchange with UK

Business growth is key to post-pandemic recovery

A new paradigm for collaboration: mission-based ecosystems

Africa is ‘on the rise’, says UN chief Guterres, urging collaboration for better future

MEPs urge UK to break current deadlock

Gender equality and medicine in the 21st century: an equity unachieved

Commission supports Member States in tackling coronavirus hotspots with offer of four million additional doses of BioNTech-Pfizer vaccine to be delivered this month

These 4 companies are turning food waste into cosmetics, clothing and more

Ahead of State of the Union the European Youth Forum highlights lack of action on youth employment

More international support needed to curb deadly measles outbreak in DR Congo

White Coat, Stained red

Gas pipeline in the European Union. (Copyright: EU, 2012 / Source: EC - Audiovisual Service / Photo: Ferenc Isza)

EU Investment Bank approves € 1.5bn loan for Trans Adriatic Pipeline (TAP)

COVID-19 has accelerated India’s digital reset

Commission celebrates the 30th anniversary of the Jean Monnet Activities promoting European studies worldwide

Meet the Seed Warrior: the man on a mission to rescue India’s rice diversity

UN rights chief ‘extremely concerned’ over deadly crackdown on protesters in Iran

Amid COVID-19 constraints, UN women’s commission meets to push gender equality forward

COVID-19, higher education and the impact on society: what we know so far and what could happen

As rural communities age, their public transport is shrinking. It’s time to fix this

Why the future of food must be blue as well as green

The digital revolution will transform the steel industry

ILO: Unemployment to increase by 8.1 million in 2013-2014

Central Mali: Top UN genocide prevention official sounds alarm over recent ethnically-targeted killings

Eco-anxiety during the Pandemic

GSMA Mobile 360 – Africa on 16-18 July 2019, in association with The European Sting

Destroying nuclear waste to create clean energy? It can be done

More Stings?

Advertising

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s